iRadimed Q2 2026 Earnings Report

iRadimed EPS Results

• Actual EPS: $0.46
• Consensus EPS: $0.44
• Beat/Miss: Beat by +$0.02
• One Year Ago EPS: N/A

iRadimed Revenue Results

• Actual Revenue: $20.47 million
• Expected Revenue: $20.35 million
• Beat/Miss: Beat by +$116.00 thousand
• YoY Revenue Growth: N/A

iRadimed Announcement Details

• Quarter: Q2 2026
• Date: 7/31/2026
• Time: Before Market Opens
• Conference Call Date: Friday, July 31, 2026
• Conference Call Time: 11:00AM ET

iRadimed (NASDAQ:IRMD) develops, manufactures and markets medical devices designed for use in magnetic resonance imaging (MRI) environments. The company focuses on equipment that enables clinicians to provide continuous care and monitor patients safely while they are undergoing MRI procedures, where conventional medical devices may pose safety or compatibility challenges.

Its product portfolio includes the MRidium MRI-compatible infusion pump systems, which are designed to deliver intravenous medications and fluids during MRI examinations, as well as MRI-compatible patient monitoring systems and related accessories. These products are intended for use in areas such as anesthesia, critical care, emergency medicine and diagnostic imaging.

Founded in 2004 and headquartered in Orlando, Florida, iRadimed serves hospitals, imaging centers and other healthcare providers in the United States and international markets through a combination of direct sales and distributors. The company was founded by Roger Susi, who has served as its president and chief executive officer.

iRadimed Q2 2026 Earnings Call Transcript

Key Takeaways

• Positive Sentiment: Strong customer demand for the new 3870 pump drove bookings to more than double units shipped, with roughly 70% of replacement orders using four-channel quad systems and ASPs exceeding $110,000.
• Positive Sentiment: IRadimed achieved its target of producing more than 130 3870 pumps in Q2 and plans to exceed 300 units in Q3, with startup costs expected to decline by more than 50% as manufacturing efficiencies improve.
• Negative Sentiment: Q2 revenue was essentially flat year over year at $20.5 million, while gross margin fell to 74% from 78% and GAAP EPS declined to $0.41 from $0.45 due to the initial 3870 production ramp.
• Positive Sentiment: Recurring revenue trends remained healthy, including 14% growth in disposables, while domestic patient-monitor sales reached a record 71 units and the company cited strong backlogs across pumps, monitors, and ferromagnetic detection systems.
• Positive Sentiment: Management reaffirmed full-year 2026 guidance of $91 million–$96 million in revenue and $1.90–$2.05 in GAAP EPS, expects improving margins through the second half, and said a $100 million revenue run rate in Q4 is within reach.

Presentation

[Operator]

Hello, welcome to the IRadimed Corporation second quarter of 2026 financial results conference call. All participants are currently in a listen-only mode. At the end of the call, we will conduct a question-and-answer session. This call is being recorded today, July the 31st, 2026, and contains time-sensitive, accurate information that is valid only for today. Earlier, IRadimed released its financial results for the second quarter of 2026. A copy of this press release announcing the company's earnings is available under the headings News on their website at iradimed.com. A copy of the press release was also furnished to the Securities and Exchange Commission on Form 8-K and can be found at sec.gov. This call is being broadcast live on the company's website at iradimed.com, and a replay will be available there for the next 90 days.

[Operator]

Some of the information in today's session will constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements focus on future performance, results, plans, and events and may include the company's expected future results. IRadimed reminds you that future results may differ materially from these forward-looking statements due to severe risk factors. For a description of the relevant risks and uncertainties that may affect the company's business, please see the Risk Factors section in the company's most recent reports filed with the Securities and Exchange Commission, which may obtain free from the SEC's website at sec.gov. I want to turn the call over to Roger Susi, President and Chief Executive Officer of IRadimed Corporation. Mr. Susi?

[Roger Susi, President and CEO at IRadimed Corporation]

Thank you, operator. Good morning and welcome to IRadimed Corp's second quarter 2026 earnings call. This quarter, we embarked on the first general release production of the new 3870 MRI IV pump system as planned, targeting, as discussed last quarter, the building of 130 to 135 of these new pumps. I'm very pleased to report that our teams performed exceptionally well and achieved our manufacturing target. No small task. Taking 3870 production from a standing start to an impressive rate in the quarter. With those efforts, we were able to achieve revenue and earnings per our guidance, with revenue of $20.5 million and earnings of $0.41 on a GAAP basis and non-GAAP earnings of $0.46 per share. As we expected and guided, the new pump launch consumed significant effort, including increased labor and overhead expenses, much of which is reflected in the quarter's gross margin of 74%.

[Roger Susi, President and CEO at IRadimed Corporation]

I want to speak to what's next, that starts with a discussion of how bookings were in the quarter, how fast we could continue to ramp the new 3870 pump production, and a short recap of our opportunity. Opportunities for the new 3870 pump system are both the increased penetration of the greenfield, which are predominantly those facilities that continue to deal with IV fluid delivery, in the MR setting via the various old-school workarounds. Expansion of current customer use requiring more pumps, as well as the quite substantial replacement of IRadimed's aged installed base of 3860 pump systems. The most immediate and significant increase coming from the large replacement opportunity. This replacement opportunity will be our key growth driver for the next several years and was indeed a significant factor for many of the orders booked in the second quarter.

[Roger Susi, President and CEO at IRadimed Corporation]

Recalling that for the U.S. market, there are approximately 6,400 five-plus-year-old 3860/3861 pump channels up for replacement. We had been selling approximately 1,100 such 3860 channels annually. With the new 3870, we target adding another 1,000 channels per year through replacement sales from those existing 6,400 old 3860 units that are over five years old. Bookings for the quarter were more than double the units shipped, showing very strong customer acceptance and quick decision-making while only scratching at the target replacement base mildly. Add to this that not only are we replacing those older two-channel pump systems, but an astounding 70% of those were replaced with our four-channel quad pump system, thus requiring twice the number of pumps. Additionally, the ASP of those quad systems has been north of $110,000, providing well over a 20% lift in the ASP per pump.

[Roger Susi, President and CEO at IRadimed Corporation]

In short, the demand is exceeding our expectations in both the number of pumps and the ASP. There's also some fantastic news with our patient monitor. Though the sales team was quite busy obtaining orders for the new 3870, they outperformed themselves and brought in a record high of 71 monitors from the domestic market while maintaining a high ASP. With a strong backlog and the sales potential we have, it comes down to the ramp-up of production and the ramp-down of costs associated with manufacturing learning curve, which we've all been climbing every day. Q2 was a huge effort with plenty of inefficiencies in cost as we went from zero to 130 plus 3870 pumps. Q3 will remain a stretch as we plan to more than double production again to over 300 units. However, we see that we are indeed riding that learning curve well and taming it.

[Roger Susi, President and CEO at IRadimed Corporation]

We expect that the startup costs experienced in Q2 will be better than 50% reduced in Q3, while earnings will reflect such a strong positive move as well. This will continue into Q4, by which time we anticipate nearing our historic manufacturing efficiencies. What's coming in Q3? Let me have Jack Glenn, our CFO, detail this for you, but I will say that as we enter Q3 with a solid backlog of our pump and monitor systems, as well as a strong backlog of FMD systems, we again, however, will be in a controlled production ramp phase. Though ramping from 130 to our Q3 production target of over 338 3870 pumps is certainly a very high ramp rate, the team is performing, and we feel confident we will deliver, along with ever more MRI patient monitoring systems as well.

[Roger Susi, President and CEO at IRadimed Corporation]

Thus, you can expect IRadimed to be heading back to and beyond the strong growth rates of the past, with expectations that by Q4, and with two early product launch quarters in the rear view, our gross margins will have not only returned but be setting new records, which fall directly to the bottom-line, of course. Now I'll turn the call over to Jack Glenn, our CFO, to review the quarter's financial results and provide a deeper color on the growth through the balance of the year.

[Jack Glenn, CFO at IRadimed Corporation]

Thank you, Roger, and good morning, everyone. As in the past, our results are reported on a GAAP basis and a non-GAAP basis. You can find a description of our non-GAAP measures in this morning's earnings release and a reconciliation to GAAP on the last page. For the three months ended June 30, 2026, revenue was $20.5 million, up 0.5% from $20.4 million in the second quarter of 2025. Pump revenue was in line with our expectations as we transition from the 3860 to the next generation 3870 pump. MRI-compatible patient vital signs monitoring systems contributed $6.7 million, up 12% year-over-year, and ferromagnetic detection systems contributed $0.8 million, up 57%. On the recurring side, disposables revenue grew 14% to $4.8 million, driven by continued increases in device utilization. Amortization of extended maintenance agreements grew 28% to $0.8 million, and services and other grew 7% to $1.1 million.

[Jack Glenn, CFO at IRadimed Corporation]

Domestic sales were 82% of total revenue in the second quarter, compared to 89% a year earlier, as domestic 3860 pump revenues were exceptionally strong in Q2 of last year. For the six months, domestic sales accounted for 82% of revenue, down from 86% a year ago. Gross profit for the quarter was $15.2 million, with a margin of 74%, compared with $16 million and 78% in the second quarter of 2025. The decline in gross margin reflects the higher manufacturing costs associated with our first sizable production ramp of the 3870. For the six months, gross profit was $32 million, with a margin of 75%, down from 77% a year earlier. We expect the gross margin to improve in the second half of the year as 3870 volumes build and manufacturing efficiencies take hold.

[Jack Glenn, CFO at IRadimed Corporation]

Total operating expenses for the quarter were $8.8 million, down 4% from $9.2 million, and 43% of revenue, compared with 45% a year ago. General and administrative expense was $3.9 million, down 10%, primarily due to lower legal and professional fees, regulatory consulting, and payroll and benefits. Sales and marketing expense was $4.2 million, up 6%, primarily due to higher sales commissions driven by the strong bookings in the quarter. Research and development expense was $0.7 million, down 25%, primarily reflecting an increase in capitalized internal software development on the next-generation monitor in the quarter. Income from operations for the quarter was $6.4 million, or 31% of revenue, compared with $6.8 million a year ago. Tax expense for the quarter was $1.7 million, with an effective tax rate of 24.2%, compared with a 21.2% rate in the second quarter of 2025. The rate differs from the U.S.

[Jack Glenn, CFO at IRadimed Corporation]

federal statutory rate, primarily due to state income tax expense, partially offset by benefits from research and development tax credits. As we stated in our first quarter call, the effective tax rate is also affected by the timing of deductions tied to the windfall deduction for equity grants, which is a discrete item taken at the time of vesting of the equity grants, most of which occur in the fourth quarter of the year. We no longer expect the windfall deduction to be as large as we originally thought, and therefore believe the effective tax rate will be likely in the 24% range for the remainder of the year. Net income for the quarter was $5.2 million, or $0.41 per diluted share, compared with $5.8 million, or $0.45 per diluted share.

[Jack Glenn, CFO at IRadimed Corporation]

Non-GAAP net income was $5.9 million, or $0.46 per diluted share, compared with $6.4 million, or $0.49 per diluted share, excluding $0.6 million of stock-based compensation expense net of tax benefit. For the six months, net income was $11 million, or $0.86 per diluted share, up 5%, and non-GAAP net income was $12.2 million or $0.95 per diluted share, up 4%. We ended the quarter with cash and cash equivalents of $59.1 million, up from $51.2 million at year-end. Cash flow from operations was $5.9 million for the quarter and $14.2 million for the six months, an increase of 18% over the first half of last year. Capital expenditures were $0.4 million for the quarter and $0.9 million for the six months, down from $6.7 million in the prior year period, which had included the construction of our new corporate office and manufacturing facility.

[Jack Glenn, CFO at IRadimed Corporation]

Our Board of Directors declared a regular quarterly cash dividend of $0.20 per share, payable on August 28th, 2026 to stockholders of record as of the close of business on August 14th, 2026. Lastly, to repeat our guidance. For the third quarter of 2026, we expect revenue of $23 million-$24.5 million, GAAP diluted earnings per share of $0.49-$0.54, and non-GAAP diluted earnings per share of $0.54-$0.59. For the full-year 2026, we reaffirm our guidance and expect revenue of $91 million-$96 million, GAAP diluted earnings per share of $1.90-$2.05, and non-GAAP diluted earnings per share of $2.09-$2.24.

[Jack Glenn, CFO at IRadimed Corporation]

Our non-GAAP earnings per share guidance excludes stock-based compensation expense and net of tax, which we expect to be approximately $2.5 million for the full-year. With that, I will turn the call over to questions. Operator?

[Operator]

Thank you. Ladies and gentlemen, to ask the question, please press star one one on your telephone, then wait for your name to be announced. To withdraw your question, please press star one one again. Please stand by while we compile the Q&A roster. Our first question comes from the line of Frank Takkinen with Lake Street Capital Markets. Your line is open.

[Analyst at Lake Street Capital Markets]

Nelson on for Frank. Good morning, Jack and Roger. I want to start with the 3870 ramp. You went from zero to 130+ pumps in Q2 and now are planning for over 300 in Q3. Can you talk a little bit more about what that requires operationally, are you adding additional shifts or production headcount, or does the existing line get you there? Does the pace keep stepping up in Q4, or how are you kind of wanting us to think about that?

[Roger Susi, President and CEO at IRadimed Corporation]

Oh, no. We kind of did the staffing stuff over the previous several months, anticipating exactly what we need to meet the demands of making the new pump. We're no longer doing that. Those expenses had been in place, and that's not where we're going. It's exactly what I mentioned a few times over. It's strictly learning curve. It's experience. The efficiencies come when the folks that are making these products, basically, it becomes sort of second nature, muscle memory, what have you. That's the experience I'm talking about. It's, at this point, cost-wise, free, but time-wise, they have to work overtime to do this learning, and they're not as efficient and as fast.

[Analyst at Lake Street Capital Markets]

Helpful. As your 3860 units are phasing out, how should we think about the service and disposable revenue attached to that install base? Maybe just talk through the 3870 quad replacement and your expectations with that for recurring revenue per site as those phase out. Is there any kind of transition gap you're thinking about, or should we not really see anything like that?

[Jack Glenn, CFO at IRadimed Corporation]

Yeah, I can get and take that one maybe. As far as the disposal revenue, you're seeing some nice growth already, right? I think in the quarter, had over 14% growth on the disposables. The 3860 install base continues, hopefully, on the same kind of utilization. What we really are excited about, and we think will help us even grow that more in the future is the quad stack. Of course, that's what we're seeing, right? That should help just really drive utilization, as you see four pumps compared to two. We're excited about the opportunity there, I think in the future on the 3870 and the utilization.

[Analyst at Lake Street Capital Markets]

Got it. Then maybe just last one. Let's say a hospital signs a quad stack order today, when are you kind of expecting that shift? Are new bookings landing maybe in Q4? Are we pushing into Q1 of next year? How is that playing out?

[Jack Glenn, CFO at IRadimed Corporation]

As far as lead time?

[Analyst at Lake Street Capital Markets]

Yeah, as far as lead time goes.

[Jack Glenn, CFO at IRadimed Corporation]

I think as far as lead times, we're able to, right now, probably get it within the next quarter kind of thing, probably, or at least orders that are coming in within three months.

[Roger Susi, President and CEO at IRadimed Corporation]

Our bookings of the new pump were more than double what we shipped. The backlog is building, and as we go through the coming quarters, I wasn't quite sure of your question, but as we go through the coming quarters, of course, what customers experience as the lead time will extend back out to more historic levels. We've had the lead times out in the four and five months zone, six months zone, through much of our history, and we're probably headed there and maybe a little more, frankly, because of the demand of this new system and because of the pleasant surprise of basically selling double the number of pumps with these quad systems.

[Analyst at Lake Street Capital Markets]

Perfect. That's helpful. Thank you, guys.

[Roger Susi, President and CEO at IRadimed Corporation]

Sure. Okay. Good to talk to you.

[Operator]

Thank you. Ladies and gentlemen, I'm showing no further questions in the queue. I would now like to turn the call back over to Roger for closing remarks.

[Roger Susi, President and CEO at IRadimed Corporation]

Thank you, operator. Well, as you heard, with the excellent customer reception of the new 3870 IV pump and continued strong sales of the 3880 patient monitor, along with production experience growing, pushing up our ability to ramp 3870s, our $100 million run-rate in Q4 is now well within our grasp. With that, I'd like to thank you all for joining today's call. I look forward to ramping production and regaining efficiencies as we capitalize on this huge opportunity before us. Thank you.

[Operator]

Thank you. This concludes the call. You may now disconnect.

Participants

Analysts

• Roger Susi, President and CEO at IRadimed Corporation
• Jack Glenn, CFO at IRadimed Corporation
• Analyst at Lake Street Capital Markets